Boston Scientific Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B | 19.9% | |
| Cost of Revenue | (4.43B) | (4.97B) | (5.41B) | (6.48B) | (6.22B) | -4.0% | |
Gross Profit | 7.46B | 7.71B | 8.83B | 10.27B | 13.85B | 34.9% | |
| Operating Expenses | |||||||
| Research & Development | (1.20B) | (1.32B) | (1.41B) | (1.61B) | (2.05B) | 27.1% | |
| Selling, General & Administrative | (4.29B) | (4.52B) | (5.19B) | (5.98B) | (6.89B) | 15.1% | |
| Depreciation & Amortization | (1.09B) | (1.14B) | (1.20B) | (1.27B) | — | -100.0% | |
Operating Income (EBIT) | 1.92B | 1.82B | 2.18B | 2.63B | 3.97B | 50.7% | |
| Non-Operating Items | |||||||
| Interest Income | 4.00M | 10.00M | 22.00M | 107.00M | — | -100.0% | |
| Interest Expense | (349.00M) | (464.00M) | (272.00M) | (387.00M) | (349.00M) | -9.8% | |
| Other Income/Expenses (Net) | -846.00M | -683.00M | -196.00M | -353.00M | -586.00M | 66.0% | |
Income Before Tax | 1.08B | 1.14B | 1.99B | 2.28B | 3.38B | 48.3% | |
| Income Tax Expense | (36.00M) | (443.00M) | (393.00M) | (436.00M) | (493.00M) | 13.1% | |
Net Income | 1.04B | 698.00M | 1.59B | 1.85B | 2.89B | 55.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $1 | $0 | $1 | $1 | $2 | 55.6% | |
| Weighted Avg Shares Outstanding | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B | 0.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B | 0.6% | |
EBITDA | 2.52B | 2.74B | 3.45B | 3.94B | 3.73B | -5.2% |
Explore BSX
BSX in the Healthcare
Large Cap